Zinc Acne Meta-analysis: What the Evidence Says
Zinc Acne Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedica
Quick Answer
Zinc Acne Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public health sources, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 1 narrative review, 1 preclinical study.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Zinc Acne Meta-analysis: What the Evidence Says
Quick Answer
Zinc Acne Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Cosmeceuticals in acne vulgaris: from mechanism of action to clinical application | narrative review | 3 | 2026-03-01 | 10.1093/skinhd/vzaf104 |
| Beyond Isotretinoin: A Narrative Review of Emerging Systemic Therapies for Moderate‐to‐Severe Acne | preclinical study | 4 | 2026-03-31 | 10.1111/jocd.70812 |
What The Sources Report
- National Institute for Health and Care Excellence (NICE) guidelines recommend azelaic acid in combination with oral antibiotics for moderate-to-severe acne or as a second-line monotherapy option if adapalene/BPO combinations are not tolerated. [Searle Tamara N (2026); evidence level 3]
- Stronger clinical support exists for the use of retinol, BPO and azelaic acid, while other cosmeceuticals such as niacinamide, zinc, tea tree oil and green tea could be promising adjuncts, although there is less robust evidence to support their use. [Searle Tamara N (2026); evidence level 3]
- Several factors contribute to the pathogenesis of acne, such as bacterial proliferation of Cutibacterium (C.) acnes, increased sebum secretion, altered follicular keratinization, and hyperandrogenism. [Tommasino Nello (2026); evidence level 4]
- In fact, acne is associated with low self-esteem, embarrassment, social anxiety, and isolation. [Tommasino Nello (2026); evidence level 4]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
For zinc acne meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Searle Tamara N (2026). Cosmeceuticals in acne vulgaris: from mechanism of action to clinical application. DOI: 10.1093/skinhd/vzaf104. PMCID: PMC13036733. PMID: 41923969. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13036733/
- Tommasino Nello (2026). Beyond Isotretinoin: A Narrative Review of Emerging Systemic Therapies for Moderate‐to‐Severe Acne. DOI: 10.1111/jocd.70812. PMCID: PMC13037353. PMID: 41914642. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13037353/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed May 27, 2026 by Migaku Evidence Review
Related content
